-+ 0.00%
-+ 0.00%
-+ 0.00%

VistaGen says FDA clears refisolone IND to proceed with Phase 2 studies

PUBT·04/28/2026 20:38:41
Listen to the news
VistaGen says FDA clears refisolone IND to proceed with Phase 2 studies
  • VistaGen received an FDA “Study May Proceed” letter under its IND for refisolone nasal spray, clearing further Phase 2 development in the US for menopausal hot flashes.
  • Refisolone is positioned as a non-hormonal, non-systemic treatment targeting moderate to severe vasomotor symptoms due to menopause.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-027930), on April 28, 2026, and is solely responsible for the information contained therein.